Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Shen, Chan Juan ^a   Yang, Yu Xiu ^a   Han, Ethan Q ^b   Cao, Na ^a   Wang, Yun Fei ^a   Wang, Yi ^a   Zhao, Ying Ying ^a   Zhao, Li Ming ^a   Cui, Jian ^c   Gupta, Puja ^c   Wong, Albert J ^c   Han, Shuang Yin ^a  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adoptive immunotherapy; Chimeric antigen receptor; Glioma

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III; GAMMA INTERFERON; INDUCIBLE T CELL COSTIMULATOR; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CANCER CELL; CD3+ T LYMPHOCYTE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; GLIOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LENTIVIRINAE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; WESTERN BLOTTING; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BRAIN NEOPLASMS; DRUG SCREENING; IMMUNOLOGY; NUDE MOUSE; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE; BRAIN TUMOR; METHODOLOGY;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEMALE; GLIOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877116624     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-33     Document Type: Article

References (24)

1. Adoptive cellular therapy. Grupp SA, June CH, Curr Top Microbiol Immunol 2011 344 149 172 20700700
2. Chimeric antigen receptors for T-cell based therapy. Cheadle EJ, Sheard V, Hombach AA, Chmielewski M, Riet T, Berrevoets C, Schooten E, Lamers C, Abken H, Debets R, Gilham DE, Methods Mol Biol 2012 907 645 666 22907378
3. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. Porter DL, Levine BL, Kalos M, Bagg A, June CH, N Engl J Med 2011 365 725 733 10.1056/NEJMoa1103849 21830940
4. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK, Blood 2011 118 6050 6056 10.1182/blood-2011-05-354449 21984804
5. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Lo AS, Ma Q, Liu DL, Junghans RP, Clin Cancer Res 2010 16 2769 2780 10.1158/1078-0432.CCR-10- 0043 20460472
6. Two signal models in innate immunity. Fontana MF, Vance RE, Immunol Rev 2011 243 26 39 10.1111/j.1600-065X.2011.01037.x 21884165
7. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH, Proc Natl Acad Sci USA 2009 106 3360 3365 10.1073/pnas.0813101106 19211796
8. CD28 Costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G, J Clin Invest 2011 121 1822 1826 10.1172/JCI46110 21540550
9. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. Finney HM, Akbar AN, Lawson AD, J Immunol 2004 172 104 113 14688315 (Pubitemid 38020461)
10. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ, Cancer Res 1995 55 5536 5539 7585629
11. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Del Vecchio CA, Li G, Wong AJ, Expert Rev Vaccines 2012 11 133 144 10.1586/erv.11.177 22309662
12. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Gan HK, Burgess AW, Clayton AH, Scott AM, Cancer Res 2012 72 2924 2930 10.1158/0008-5472.CAN-11-3898 22659454
13. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE 2nd, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD, Mol Cancer Ther 2009 8 2773 2779 10.1158/1535-7163.MCT-09-0124 19825799
14. Development of an EGFRvIII specific recombinant antibody. Gupta P, Han SY, Holgado-Madruga M, Mitra SS, Li G, Nitta RT, Wong AJ, BMC Biotechnol 2010 10 72 10.1186/1472-6750-10-72 20925961
15. Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission. Wu L, Martin TD, Vazeux R, Unutmaz D, KewalRamani VN, J Virol 2002 76 5905 5914 10.1128/JVI.76.12.5905-5914.2002 12021323 (Pubitemid 34556285)
16. 4-1BB And CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, June CH, Wagner JE, Blazar BR, Zhou X, Hum Gene Ther 2010 21 75 86 10.1089/hum.2009.122 19719389
17. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH, Sci Transl Med 2011 3 95ra73 10.1126/scitranslmed.3002842 21832238
18. Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells. Sasaki T, Ikeda H, Sato M, Ohkuri T, Abe H, Kuroki M, Onodera M, Miyamoto M, Kondo S, Nishimura T, Cancer Sci 2006 97 920 927 10.1111/j.1349-7006.2006.00271. x 16856879 (Pubitemid 44151274)
19. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M, Nat Biotechnol 2012 31 71 75 10.1038/nbt.2459 23242161
20. + T cell-mediated tumor eradication. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M, Mol Ther 2010 18 413 420 10.1038/mt.2009.210 19773745
21. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Ohno M, Natsume A, Ichiro Iwami K, Iwamizu H, Noritake K, Ito D, Toi Y, Ito M, Motomura K, Yoshida J, Yoshikawa K, Wakabayashi T, Cancer Sci 2010 101 2518 2524 10.1111/j.1349-7006.2010.01734.x 20880333
22. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. Bullain SS, Sahin A, Szentirmai O, Sanchez C, Lin N, Baratta E, Waterman P, Weissleder R, Mulligan RC, Carter BS, J Neurooncol 2009 94 373 382 10.1007/s11060-009-9889-1 19387557
23. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA, Hum Gene Ther 2012 23 1043 1053 10.1089/hum.2012.041 22780919
24. New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM, Miller JS, Mostoslavsky G, Powell DJ Jr, Rao M, Restifo NP, Rosenberg SA, O'Shea J, Melief CJ, J Transl Med 2012 10 48 10.1186/1479-5876-10-48 22420641